ClinConnect ClinConnect Logo
Search / Trial NCT05991830

Inflammatory Markers and Level of Cortical Hyperactivity

Launched by UNIVERSITY OF CHILE · Aug 7, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is investigating how certain inflammatory markers in the body relate to brain activity in older adults with cognitive disorders, particularly those who may be experiencing early signs of Alzheimer's disease. Researchers are looking to understand how inflammation, indicated by specific proteins in the blood, affects brain activity when patients are given a common anesthetic called propofol during elective surgeries.

To participate in this study, you need to be over 60 years old and scheduled for an elective surgery. It's important that you can understand and agree to participate by signing a consent form. However, if you have any other serious brain conditions, active illnesses, severe mental health issues, or an allergy to propofol, you won't be eligible. If you join the trial, you will undergo some tests to measure your brain's electrical activity while being given propofol, helping researchers learn more about the connections between inflammation and brain function in older adults.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Adults over 60 years of age undergoing elective surgery
  • 2. Able to understand and sign an informed consent form
  • Exclusion Criteria:
  • 1. Diagnosis of other neurological pathologies
  • 2. No active acute or chronic decompensated diseases
  • 3. No severe psychiatric illnesses
  • 4. Propofol allergy

About University Of Chile

The University of Chile, a leading academic institution in South America, is dedicated to advancing medical research and improving public health through innovative clinical trials. With a strong emphasis on collaboration among multidisciplinary teams, the university leverages its extensive resources and expertise to conduct rigorous and ethically sound studies. By integrating cutting-edge scientific methodologies and fostering partnerships with healthcare providers, the University of Chile aims to contribute valuable insights to the medical community and enhance patient care both locally and globally.

Locations

Santiago, Rm, Chile

Santiago, Rm, Chile

Patients applied

0 patients applied

Trial Officials

Pedro Lobos, PhD

Principal Investigator

University of Chile

Antonello Penna, MD, PhD

Study Chair

University of Chile

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported